Lansing, MINCT06107738Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Lansing, MI

Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Lansing. Study-provided care at no cost to qualified participants.

Sponsored by Barbara Ann Karmanos Cancer Institute

Quick Self-Assessment

See if you qualify for this Lansing location

Preparing your pre-screening questions...

Expert Care in Lansing

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Lansing Location

Check if you qualify for this multiple myeloma clinical trial in Lansing, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lansing

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lansing site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in Lansing

The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are: * Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with resi

Sponsor: Barbara Ann Karmanos Cancer Institute

Who Can Participate

Inclusion Criteria

Multiple Myeloma patients who have received prior DARA-containing induction therapy and have attained at least a partial response. 2. Patients who have completed Autologous Stem Cell Transplant (ASCT) 90-150 days prior to registration, without any post-ASCT therapy and without post-ASCT disease progression (according to IMWG criteria) 3. Patients who are Minimal Residual Disease positive (MRD (+)) as measured by the ClonoSEQ assay using a sensitivity of 10-5, measured 90-150 days following ASCT. 4. Prior DARA-containing induction therapy (at least 3 cycles), attaining at least a partial response. 5. Completed ASCT within 90-150 days prior to registration, without any post-ASCT therapy and without evidence of post-ASCT disease progression (according to IMWG criteria) 6. MRD (+) at the time of study enrollment using the clonoSEQ NGS (next-generation sequencing) assay. Patients with an M-spike of ≥ 0.5 g/dL and/or an abnormal free light chain ratio (with an involve

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lansing?

Yes, this clinical trial (NCT06107738) has an active research site in Lansing, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Lansing, MI

If you're searching for multiple myeloma treatment options in Lansing, MI, this clinical trial (NCT06107738) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lansing research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Lansing, MI

See all multiple myeloma clinical trials recruiting in Lansing — not just this study.

Browse Multiple Myeloma Trials in Lansing →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Lansing?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lansing, MI